Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current issues with beta2-adrenoceptor agonists: historical background.

Anne E Tattersfield1

  • 1Division of Respiratory Medicine, University of Nottingham, Clinical Sciences Building, Nottingham University Hospital, City Hospital Campus, Nottingham, England. anne.tattersfield@nottingham.ac.uk

Clinical Reviews in Allergy & Immunology
|November 7, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Doxycycline in lymphangioleiomyomatosis: not all questions are answered.

The European respiratory journal·2014
Same author

A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis.

The European respiratory journal·2013
Same author

Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2011
Same author

Quadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: a randomized, double-blind, placebo-controlled, parallel-group clinical trial.

American journal of respiratory and critical care medicine·2009
Same author

Systemic and bronchodilator effects of inhaled rac-formoterol in subjects with chronic obstructive pulmonary disease: a dose-response study.

British journal of clinical pharmacology·2008
Same author

Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help?

The British journal of general practice : the journal of the Royal College of General Practitioners·2008
Same journal

β-blocker Therapy in Cholinergic Urticaria, Adrenergic Urticaria and the Aquagenic Continuum Beta-Blocker Therapy in Chronic Inducible Urticaria.

Clinical reviews in allergy & immunology·2026
Same journal

Immunopathogenesis and Cytokine Pathways in Reactive Infectious Mucocutaneous Eruption (RIME) in Pediatric Population: Infectious Triggers and Molecular Insights.

Clinical reviews in allergy & immunology·2026
Same journal

Neuropsychological Factors in Vitiligo: Mechanisms and Clinical Application.

Clinical reviews in allergy & immunology·2026
Same journal

Tertiary Lymphoid Structure: A Potential Therapeutic Target Affecting Immune Response in Autoimmune Diseases.

Clinical reviews in allergy & immunology·2026
Same journal

Differentiating Acute-onset Autoimmune Hepatitis From Drug-Induced Autoimmune-like Hepatitis: A Multicenter Study and Score Development.

Clinical reviews in allergy & immunology·2026
Same journal

Mapping Neuro Behcet's Disease Across North Africa: a Systematic Review and Meta Analysis.

Clinical reviews in allergy & immunology·2026
See all related articles

Early asthma treatments involved adrenal extracts, leading to adrenaline isolation and the development of beta2-agonists. Selective beta2-agonists and improved inhaler technology enhanced asthma management in the 20th century.

Area of Science:

  • Pharmacology
  • Respiratory Medicine

Background:

  • Organotherapy in the late 19th century led to investigating adrenal glands for asthma treatment.
  • Adrenaline (epinephrine), an adrenal hormone with sympathomimetic properties, was isolated and synthesized in 1901.

Observation:

  • The first nonselective beta-agonist, isoproterenol, was isolated in 1940.
  • Selective beta2-agonists were developed in the 1960s, followed by long-acting beta2-agonists in the 1990s.

Findings:

  • Beta2-selectivity significantly reduced adverse effects associated with asthma medications.
  • Advancements in inhaler technology enabled targeted delivery of smaller drug doses to the airways.

Implications:

  • Beta2-agonists represent crucial 20th-century pharmaceutical developments for respiratory conditions.

Related Experiment Videos

  • Extensive research has focused on optimizing beta2-agonist efficacy and minimizing side effects over the past 50 years.